Literature DB >> 26428631

Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis.

K L Schully1, M G Bell1, A M Prouty1, M D Gallovic2, S Gautam3, K J Peine4, S Sharma3, E M Bachelder4, J T Pesce1, M A Elberson1, K M Ainslie5, A Keane-Myers1.   

Abstract

Melioidosis, a potentially lethal disease of humans and animals, is caused by the soil-dwelling bacterium Burkholderia pseudomallei. Due to B. pseudomallei's classification as a Tier 1 Select Agent, there is substantial interest in the development of an effective vaccine. Yet, despite decades of research, no effective target, adjuvant or delivery vehicle capable of inducing protective immunity against B. pseudomallei infection has been identified. We propose a microparticulate delivery vehicle comprised of the novel polymer acetalated dextran (Ac-DEX). Ac-DEX is an acid-sensitive biodegradable carrier that can be fabricated into microparticles (MPs) that are relatively stable at pH 7.4, but rapidly degrade after phagocytosis by antigen presenting cells where the pH can drop to 5.0. As compared to other biomaterials, this acid sensitivity has been shown to enhance cross presentation of subunit antigens. To evaluate this platform as a delivery system for a melioidosis vaccine, BALB/c mice were vaccinated with Ac-DEX MPs separately encapsulating B. pseudomallei whole cell lysate and the toll-like receptor (TLR) 7/8 agonist resiquimod. This vaccine elicited a robust antibody response that included both Th1 and Th2 immunity. Following lethal intraperitoneal challenge with B. pseudomallei 1026b, vaccinated mice demonstrated a significant delay to time of death compared to untreated mice. The formulation, however, demonstrated incomplete protection indicating that lysate protein offers limited value as an antigen. Nevertheless, our Ac-DEX MPs may offer an effective delivery vehicle for a subunit B. psuedomallei vaccine.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acid-labile; Bacterial vaccine; Biodegradable polymer; Bioterrorism agent; Subunit vaccine

Mesh:

Substances:

Year:  2015        PMID: 26428631     DOI: 10.1016/j.ijpharm.2015.09.059

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

Review 1.  Novel multi-component vaccine approaches for Burkholderia pseudomallei.

Authors:  L Morici; A G Torres; R W Titball
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

2.  A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.

Authors:  Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

3.  A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity.

Authors:  Rebekah Watkins-Schulz; Pamela Tiet; Matthew D Gallovic; Robert D Junkins; Cole Batty; Eric M Bachelder; Kristy M Ainslie; Jenny P Y Ting
Journal:  Biomaterials       Date:  2019-03-14       Impact factor: 12.479

Review 4.  Natural-Product-Based Solutions for Tropical Infectious Diseases.

Authors:  Oyelola Adegboye; Matt A Field; Andreas Kupz; Saparna Pai; Dileep Sharma; Michael J Smout; Phurpa Wangchuk; Yide Wong; Claire Loiseau
Journal:  Clin Microbiol Rev       Date:  2021-09-08       Impact factor: 50.129

5.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

6.  Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications.

Authors:  Kathryn M Moore; Cole J Batty; Rebeca T Stiepel; Christopher J Genito; Eric M Bachelder; Kristy M Ainslie
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-24       Impact factor: 9.229

7.  Disease-Triggered Drug Release Effectively Prevents Acute Inflammatory Flare-Ups, Achieving Reduced Dosing.

Authors:  Alexandra Stubelius; Wangzhong Sheng; Sangeun Lee; Jason Olejniczak; Monica Guma; Adah Almutairi
Journal:  Small       Date:  2018-07-15       Impact factor: 13.281

Review 8.  Carbohydrate Conjugates in Vaccine Developments.

Authors:  Shuyao Lang; Xuefei Huang
Journal:  Front Chem       Date:  2020-04-15       Impact factor: 5.221

9.  Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.

Authors:  Christopher J Genito; Cole J Batty; Eric M Bachelder; Kristy M Ainslie
Journal:  Adv Nanobiomed Res       Date:  2021-01-18

10.  Vaccines for the Prevention of Melioidosis and Glanders.

Authors:  Monica M Johnson; Kristy M Ainslie
Journal:  Curr Trop Med Rep       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.